Journal of Clinical Endocrinology & Metabolism, Vol 75, 1220-1225, Copyright © 1992 by Endocrine Society

ARTICLES

Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women

J Rabinovici, P Rothman, SE Monroe, C Nerenberg and RB Jaffe
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco 94143.

A potent and safe GnRH antagonist has been sought unsuccessfully for the last 2 decades. The recently developed GnRH antagonist RS-26306 or Ganirelix ([N-Ac-D-Nal(2)1,D-pClPhe2,D-Pal(3)3,D-hArg(Et2)6,L-++ +hArg(Et2)8,D-Ala10]GnRH ; Syntex Research, Palo Alto, CA), exhibited high antiovulatory potency and low histamine-releasing properties in preclinical studies. Therefore, we determined the extent to which single sc injections of three doses of RS-26306 (1, 3, and 6 mg) decreased serum concentrations of LH and FSH, the free alpha-subunit of LH/FSH/TSH, PRL, and testosterone in five healthy postmenopausal women. We also examined the pharmacokinetic characteristics of RS-26306 by quantifying serum levels of the drug by RIA. RS-26306 rapidly suppressed serum concentrations of LH, FSH, and free alpha-subunit. RS- 26306 (6 mg) maximally decreased serum concentrations (mean +/- SEM) of LH, FSH, and free alpha-subunit by 70.1 +/- 3.6%, 42.3 +/- 2.5%, and 74.6 +/- 3.5%, respectively. RS-26306 also decreased serum testosterone, but not serum PRL, concentrations. RS-26306 concentrations reached peak serum levels at 1.2 +/- 0.3, 1.9 +/- 0.4, and 1.8 +/- 0.5 h, respectively, after 1-, 3-, and 6-mg sc injections. The mean serum half-life values based on the terminal portion of the disappearance curves were 22.8 +/- 2.5 and 26.9 +/- 1.0 h, respectively, after 3- and 6-mg s.c. doses. No systemic side-effects were noted after the administration of RS-26306. Our results demonstrate that the GnRH antagonist RS-26306 has favorable pharmacokinetic characteristics and is a potent suppressor of pituitary gonadotropin secretion in postmenopausal women. These attributes and the lack of systemic side-effects make RS-26306 a promising candidate for future clinical applications.

This article has been cited by other articles:

				R. S. Struthers, T. Chen, B. Campbell, R. Jimenez, H. Pan, S. S. C. Yen, and H. P. Bozigian Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902) J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3903 - 3907. [Abstract] [Full Text] [PDF]

				N. F. Vlahos, C. W. Lipari, B. Bankowski, T.-H. Lai, J. A. King, I.-M. Shih, K. Fragakis, and Y. Zhao Effect of Luteal-Phase Support on Endometrial L-Selectin Ligand Expression after Recombinant Follicle-Stimulating Hormone and Ganirelix Acetate for in Vitro Fertilization J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4043 - 4049. [Abstract] [Full Text] [PDF]

				T. Lainas, J. Zorzovilis, G. Petsas, G. Stavropoulou, H. Cazlaris, V. Daskalaki, G. Lainas, and E. Alexopoulou In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF Hum. Reprod., September 1, 2005; 20(9): 2426 - 2433. [Abstract] [Full Text] [PDF]

				P. Y. Liu, P. Y. Takahashi, P. D. Roebuck, A. Iranmanesh, and J. D. Veldhuis Age-specific changes in the regulation of LH-dependent testosterone secretion: assessing responsiveness to varying endogenous gonadotropin output in normal men Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R721 - R728. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, N. J. D. Veldhuis, D. M. Keenan, and A. Iranmanesh Age diminishes the testicular steroidogenic response to repeated intravenous pulses of recombinant human LH during acute GnRH-receptor blockade in healthy men Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E775 - E781. [Abstract] [Full Text] [PDF]

				W. de Ronde, A. Hofman, H. A P Pols, and F. H de Jong A direct approach to the estimation of the origin of oestrogens and androgens in elderly men by comparison with hormone levels in postmenopausal women Eur. J. Endocrinol., February 1, 2005; 152(2): 261 - 268. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis and A. Iranmanesh Pulsatile Intravenous Infusion of Recombinant Human Luteinizing Hormone under Acute Gonadotropin-Releasing Hormone Receptor Blockade Reconstitutes Testosterone Secretion in Young Men J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4474 - 4479. [Abstract] [Full Text] [PDF]

				D. Meirow, G. Assad, J. Dor, and J. Rabinovici The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum. Reprod., June 1, 2004; 19(6): 1294 - 1299. [Abstract] [Full Text] [PDF]

				C. R. McCartney, A. B. Bellows, M. B. Gingrich, Y. Hu, W. S. Evans, J. C. Marshall, and J. D. Veldhuis Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E902 - E908. [Abstract] [Full Text] [PDF]

				S. L. Wong, D. T.-W. Lau, S. A. Baughman, N. Fotheringham, D. Menchaca, and M. B. Garnick Pharmacokinetics and Pharmacodynamics of a Novel Depot Formulation of Abarelix, a Gonadotropin-Releasing Hormone (GnRH) Antagonist, in Healthy Men Ages 50 to 75 J. Clin. Pharmacol., May 1, 2004; 44(5): 495 - 502. [Abstract] [Full Text]

				S. Jabara, L. K. Christenson, C. Y. Wang, J. M. McAllister, N. B. Javitt, A. Dunaif, and J. F. Strauss III Stromal Cells of the Human Postmenopausal Ovary Display a Distinctive Biochemical and Molecular Phenotype J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 484 - 492. [Abstract] [Full Text] [PDF]

				B. Couzinet, G. Meduri, M. G. Lecce, J. Young, S. Brailly, H. Loosfelt, E. Milgrom, and G. Schaison The Postmenopausal Ovary Is Not a Major Androgen-Producing Gland J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5060 - 5066. [Abstract] [Full Text] [PDF]

				T. European Middle East Orgalutran Study Group* Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation Hum. Reprod., April 1, 2001; 16(4): 644 - 651. [Abstract] [Full Text] [PDF]

				The European Orgalutran Study Group, G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum. Reprod., July 1, 2000; 15(7): 1490 - 1498. [Abstract] [Full Text] [PDF]